BioSpace News Archive

Nordic Pharma, Inc., a subsidiary of Nordic Group B.V., has launched LACRIFILL Canalicular Gel, a novel therapy for dry eye in the U.S. LACRIFILL Canalicular Gel is a cross-linked hyaluronic acid derivative and is FDA-cleared to temporarily block tear drainage by the occlusion of the canalicular system.

BostonGene, a leading provider of AI-driven molecular and immune profiling solutions, today announced that seven abstracts have been accepted for the 2024 ASCO Annual Meeting (ASCO), scheduled to take place May 31 – June 3, 2024, at McCormick Place Convention Center in Chicago, IL.

The Roxbury Institute, globally recognized for its groundbreaking contributions to lipedema treatment, and home to the Advanced Lipedema Treatment program, proudly announces the appointment of Karen Herbst, Ph.D., M.D., as Head of Research and Director of Diagnostic and Preventative Medicine.

Alterity Therapeutics, a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, will be hosting an investor webcast on Thursday, 30 May 2024 in Australia / Wednesday, 29 May 2024 in the United States.

Full-Life Technologies, a fully integrated global radiotherapeutics company, announced it has received clearance of its Investigational New Drug Application from the U.S. Food and Drug Administration for clinical trials of 225Ac-FL-020, its PSMA-targeted radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer.

Novotech, the global full-service clinical Contract Research Organization that partners with biotech companies to accelerate the development of advanced and novel therapeutics at every phase, announced it has signed a Memorandum of Understanding with Hong Kong-Shenzhen Innovation and Technology Park Limited.

Aeterna Zentaris Inc. announced that it is making an application for an order pursuant to section 133 of the Canada Business Corporations Act extending the time for the Company to call and hold its annual meeting of its shareholders to a date that is not later than July 31, 2024.

Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd., announced that the U.S. Food and Drug Administration has approved AUSTEDO XR as a one pill, once-daily treatment option, now with four new tablet strengths indicated in adults for TD and HD chorea.

Bruker Corporation announced the pricing of its previously announced underwritten registered public offering of 6,000,000 shares of its common stock.

Merus N.V., a clinical-stage oncology company developing innovative, full-length multispecific antibodies, announced the pricing of an upsized underwritten public offering of 7,550,000 common shares, at a public offering price of $53.00 per share.